International travel and health

Proposed Guideline development group (GDG) for the revision of WHO International Travel Health

Purpose of the proposed GDG for the revision of WHO International Travel Health (Green book)

WHO provides the latest, evidence-based, travel health guidance for medical professionals, travellers and Member States. Its flagship publication, “International travel and health” (ITH), the “green book”, requires regular, evidence-based updates. It is noted that the WHO green book revision process is the most stringent one but has fewest available resources. Since 2012, the revision process follows the procedures of the WHO Guidelines Review Committee (GRC) and includes, as far as possible, a systematic and rigorous evaluation of available evidence and a transparent decision-making process for issuance of recommendations.

GDG will be established in order to revise the following seven priority areas in the WHO ITH book that no other programmes are covering, in accordance with WHO guideline development procedures:

  • Traveller diarrhoea (antibiotics and anti-diarrhoea agents)
  • Aspirin for deep vein thrombosis
  • Use of sleep inducing medication for long flights
  • Melatonin for jet lag
  • Phobia of flying
  • Altitude sickness prevention and treatment
  • Hypothermia

The revision and guideline development of areas covered by other programmes relevant to ITH book, such as vaccine-preventable diseases, malaria, etc., is out of the scope of this proposed GDG. The secretariat will coordinate with relevant programmes at a later date.

Expected timeline

Expected publication: March 2020

Proposed members of the GDG for the revision of WHO International Travel Health

Below are the names and short biographies of proposed members of the Guideline Development Group*. Comments can be sent to


Michael Adjabeng

International Health Regulations National Focal Person and Coordinator of the Port Health Unit, Public Health Division of the Ghana Health Service

Metrek Ali Almetrek

Director of Health Promotion, Ministry of Health, Saudi Arabia

Jesse Reis Alves

Medical Manager for Vaccines – GSK Brazil

Carmen Aramburu

Director of Health and Social Policy in Catalonia, Ministry of Health, Spain

Lucille Blumberg

Deputy Director of the National Institute for Communicable Diseases, of the National Health Laboratory Service, and Head of the Public Health Surveillance and Response Division, South Africa

Andrea Boggild

Associate Professor in the Department of Medicine at the University of Toronto, and Medical Director of the Tropical Disease Unit in the Division of Infectious Diseases at Toronto General Hospital, Canada

Gary Brunette

Branch Chief - Travelers’ Health Branch Division of Global Migration and Quarantine Centers for Disease Control and Prevention, Atlanta, USA

Pauline Byakika

Physician and Epidemiologist, and Associate Professor of Internal Medicine at Makerere University College of Health Sciences (MakCHS)

Carmen Cretu

Associate Professor – Parasitology Department, University of Medicine and Pharmacy, Bucharest, Romania

Albert Frederick De Frey

Senior Honorary Lecturer in the School of Public Health, Faculty of Health Sciences at the University of the Witwatersrand, South Africa

Andrew Forsyth

Manager, Public Health Capability, Ministry of Health, New Zealand

Andrea Grout

Final year PhD candidate at James Cook University, Australia, investigating the role of airlines in infectious disease control in national and international air travel

Imnadze Paata

Science Director, National Center for Disease Control and Public Health (NCDC), Tbilisi, Georgia

Lisa Indar

Head of the Regional Tourism and Health Program (THP) and Foodborne Diseases at the Caribbean Public Health Agency (CARPHA), Trinidad & Tobago

Michael Libman

Director of the J.D. MacLean Centre for Tropical Diseases at McGill University, Canada. Former Director of the Division of Infectious Diseases at McGill University and the McGill University Health Centre, Canada

Sarah McGuinness

Infectious diseases physician, lecturer and researcher at the Alfred Hospital and Monash University in Melbourne, Australia

Mohamed Moussif

Chief Medical Officer at Casablanca International Airport, Morocco

Prativa Pandey

Former President, International Society of Travel Medicine. Founding President, Nepal Travel Medicine Society. Member, Medical Advisory Board, Himalayan Rescue Association

Dipti Patel

Director of the National Travel Health Network and Centre (NaTHNaC), United Kingdom. Chief Medical Officer at the Foreign and Commonwealth Office (FCO), United Kingdom

Patricia Schlagenhauf

Professor and Senior Scientist at the University of Zürich Centre for Travel Medicine. Co-Director of the WHO Collaborating Centre for Travellers’ Health at the Institute for Epidemiology, Biostatistics and Prevention UZH, Zürich, Switzerland

Tadashi Shinozuka

Director of Sendagaya International Clinic, Japan Adjunct Professor of Chiba University, Japan Former Executive Director of Japanese Society of Travel Medicine, Japan

Leonardus Visser

Head of Department of Infectious Diseases and Deputy Director of Internal Medicine Residency Program, Leiden University Medical Centre (LUMC), The Netherlands

Last update:

25 February 2019 10:19 CET

In order to enhance its management of conflicts of interest as well as strengthen public trust and transparency in connection with WHO meetings and activities involving the provision of technical/normative advice, the names and brief biographies of individuals (“Published Information”) being considered for participation in a WHO-convened Guideline Development Group are disclosed for public notice and comment.

The Published Information is provided by the experts themselves and is the sole responsibility of the individuals concerned. WHO is not responsible for the accuracy, veracity and completeness of the Published Information provided. Furthermore, in no event will WHO be responsible or liable for damages in relation to the use of, and reliance upon, the Published Information.

The comments received by WHO through the public notice and comment process are treated confidentially and their receipt will be acknowledged through a generic email notification to the sender. Comments brought to the attention of WHO through this process are an integral component of WHO’s conflict of interest assessment process and are carefully reviewed. WHO reserves the right to discuss information received through this process with the relevant expert and disclose to this expert the name and affiliation of the provider of such information. Upon review and assessment of the information received through this process, WHO, in its sole discretion, may take appropriate management action in accordance with its policies.

Guideline Development Groups provide technical and/or normative advice and recommendations to WHO. Participation in a Guideline Development Group convened by WHO does not necessarily mean that the views expressed by the expert concerned are shared by WHO and/or represent the decisions or stated policy of WHO.

The list of participating experts, a summary of relevant interests disclosed by such experts, and any appropriate mitigation measures taken by WHO relating to the management of conflicts of interests, will be reported publically in accordance with WHO policies.